GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » Insider Ownership

Nicox (LTS:0RCQ) Insider Ownership : 0.00 % (As of Apr. 27, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Nicox Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nicox's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nicox's Institutional Ownership is 3.16%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nicox's Float Percentage Of Total Shares Outstanding is 0.00%.

Nicox Insider Ownership Historical Data

The historical data trend for Nicox's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Insider Ownership Chart

Nicox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nicox Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nicox Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Nicox Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » Insider Ownership
Comparable Companies
XPAR:ALVAL XPAR:AELIS XPAR:ALDVI XPAR:ALNFL XPAR:POXEL XPAR:ALPAT XPAR:ALVIO XPAR:ALVET XPAR:ALTAO XPAR:ALGEN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
NICXF:USA ALCOX:France NXOA:Germany
Address
Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Website
https://www.nicox.com
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines